Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Knee Osteoarthritis With Allogenic Mesenchymal Stem Cells

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Knee osteoarthritis grade II, III and IV of Kellgren and Lawrence assessed by two observers.~* Chronic knee pain with mechanical characteristics.~* No local or systemic septic process.~* Haematological and biochemical analysis without significant alterations that contraindicate treatment.~* Informed written consent of the patient.~* The patient is able to understand the nature of the study~Exclusion Criteria:~* Age over 75 or under 18 years or legally dependent~* Present Infection (to be included in the study no signs of infection must be evidenced)~* Congenital or acquired malformation resulting in significant deformity of the knee (varus\<10º; valgus\<20º) and leading to problems in application or evaluation of results.~* Overweight expressed as body mass index (BMI) greater than 30.5 (obesity grade II). BMI estimated as mass (kg) / corporal surface (m2).~* Women who are pregnant or intend to become pregnant or breast-feeding~* Neoplasia~* Immunosuppressive states~* Intra-articular infiltartion of any treatments in the last 3 months previous to study inclusion~* Participation in another clinical trial or treatment with a different investigational product within 30 days prior to inclusion in the study.~* Other pathologic conditions or circumstances that difficult participation in the study according to medical criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Allogenic mesenchymal stromal cells injection (Type: EXPERIMENTAL): Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intraarticular injection of 40 millions MSC.
- Hyaluronic acid (Durolane) (Type: ACTIVE_COMPARATOR): Intraarticular injection of hyaluronic acid (60 mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).